Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M

NCT07079670 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07079670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07079670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
October 9, 2025
Completion date
May 11, 2026
Enrollment
676 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection